Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
出版年份 2022 全文链接
标题
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
作者
关键词
-
出版物
BIODRUGS
Volume 36, Issue 3, Pages 231-323
出版商
Springer Science and Business Media LLC
发表日期
2022-04-27
DOI
10.1007/s40259-022-00529-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19
- (2022) Fatema Tuz Zahra et al. ANNALS OF THE RHEUMATIC DISEASES
- SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
- (2022) Wanwisa Dejnirattisai et al. CELL
- Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2
- (2022) Pengcheng Han et al. CELL
- Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron
- (2022) Zhen Cui et al. CELL
- Omicron’s message on vaccines: Boosting begets breadth
- (2022) Duane R. Wesemann CELL
- Y380Q novel mutation in receptor-binding domain of SARS-CoV-2 spike protein together with C379W interfere in the neutralizing antibodies interaction
- (2022) Ivaine Tais Sauthier Sartor et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance
- (2022) Jiahui Chen et al. Journal of Chemical Information and Modeling
- Emergence of Omicron third lineage BA.3 and its importance
- (2022) Perumal A. Desingu et al. JOURNAL OF MEDICAL VIROLOGY
- The puzzling mutational landscape of the SARS‐2‐variant Omicron
- (2022) Jacques Fantini et al. JOURNAL OF MEDICAL VIROLOGY
- Omicron BA.2 lineage spreads in clusters and is concentrated in Denmark
- (2022) Perumal A. Desingu et al. JOURNAL OF MEDICAL VIROLOGY
- Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity
- (2022) Bo Meng et al. NATURE
- Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
- (2022) Delphine Planas et al. NATURE
- Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
- (2022) Juan Manuel Carreño et al. NATURE
- Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
- (2022) Elisabetta Cameroni et al. NATURE
- Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
- (2022) Huiping Shuai et al. NATURE
- SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo
- (2022) Kenrie P. Y. Hui et al. NATURE
- Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
- (2022) Sandile Cele et al. NATURE
- Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
- (2022) Raquel Viana et al. NATURE
- Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant
- (2022) Rigel Suzuki et al. NATURE
- Why does the Omicron sub-variant spread faster than the original?
- (2022) Ewen Callaway NATURE
- SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
- (2022) Peter J. Halfmann et al. NATURE
- Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
- (2022) Lihong Liu et al. NATURE
- Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant
- (2022) Roby P. Bhattacharyya et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies
- (2022) S. Momsen Reincke et al. SCIENCE
- Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera
- (2022) Alexander Muik et al. SCIENCE
- The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans
- (2022) Yueh-Ming Loo et al. Science Translational Medicine
- Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant
- (2022) Baisheng Li et al. Nature Communications
- A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies
- (2022) Fortunato Ferrara et al. Nature Communications
- Cryo-EM structure of the SARS-CoV-2 Omicron spike
- (2022) Gabriele Cerutti et al. Cell Reports
- Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants
- (2022) Fengze Wang et al. Emerging Microbes & Infections
- Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods — United States, December 2020–January 2022
- (2022) A. Danielle Iuliano et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Efficacy of High-Dose Polyclonal Intravenous Immunoglobulin in COVID-19: A Systematic Review
- (2022) Daniele Focosi et al. Vaccines
- Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
- (2022) Jingjing Zhang et al. mAbs
- Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement
- (2022) Matthew McCallum et al. SCIENCE
- Evidence of SARS-CoV2 Entry Protein ACE2 in the Human Nose and Olfactory Bulb
- (2021) Moritz Klingenstein et al. CELLS TISSUES ORGANS
- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
- (2021) Robert L. Gottlieb et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evolution of antibody immunity to SARS-CoV-2
- (2021) Christian Gaebler et al. NATURE
- (A Little) Clarity on Convalescent Plasma for Covid-19
- (2021) Louis M. Katz NEW ENGLAND JOURNAL OF MEDICINE
- Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
- (2021) Michael J. Joyner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody
- (2021) C. Garrett Rappazzo et al. SCIENCE
- Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
- (2021) Tyler N. Starr et al. SCIENCE
- Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape
- (2021) Paul-Albert Koenig et al. SCIENCE
- Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry
- (2021) Jiwan Ge et al. Nature Communications
- Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape
- (2021) Zhiqiang Ku et al. Nature Communications
- A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein
- (2021) Cheolmin Kim et al. Nature Communications
- No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor
- (2021) Jarrod Shilts et al. Scientific Reports
- Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19)
- (2021) Salma Bessalah et al. 3 Biotech
- Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021
- (2021) Summer E. Galloway et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- The antigenic anatomy of SARS-CoV-2 receptor binding domain
- (2021) Wanwisa Dejnirattisai et al. CELL
- Extremely potent human monoclonal antibodies from COVID-19 convalescent patients
- (2021) Emanuele Andreano et al. CELL
- Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
- (2021) Emma C. Thomson et al. CELL
- Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
- (2021) Emma S. Winkler et al. CELL
- Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite
- (2021) Gabriele Cerutti et al. Cell Host & Microbe
- High neutralizing potency of swine glyco‐humanized polyclonal antibodies against SARS‐CoV‐2
- (2021) Bernard Vanhove et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library
- (2021) Yu Jung Kim et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
- (2021) Pengfei Wang et al. NATURE
- SARS-CoV-2 evolution during treatment of chronic infection
- (2021) Steven A. Kemp et al. NATURE
- Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
- (2021) Rita E. Chen et al. NATURE MEDICINE
- Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics
- (2021) Christoph Muus et al. NATURE MEDICINE
- Neutralizing antibodies targeting the SARS‐CoV ‐2 receptor binding domain isolated from a naïve human antibody library
- (2021) Benjamin N. Bell et al. PROTEIN SCIENCE
- Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19
- (2021) Fasihul A Khan et al. THORAX
- Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial
- (2021) Benjamin Gaborit et al. Trials
- SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface
- (2021) Federico Bertoglio et al. Nature Communications
- Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2
- (2021) Romain Gasser et al. Cell Reports
- Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies
- (2021) Darrell O. Ricke Frontiers in Immunology
- End‐to‐end continuous bioprocessing: Impact on facility design, cost of goods, and cost of development for monoclonal antibodies
- (2021) Hanna Mahal et al. BIOTECHNOLOGY AND BIOENGINEERING
- Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
- (2021) Naveenchandra Suryadevara et al. CELL
- N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
- (2021) Matthew McCallum et al. CELL
- SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
- (2021) Markus Hoffmann et al. CELL
- Antibody evasion by the P.1 strain of SARS-CoV-2
- (2021) Wanwisa Dejnirattisai et al. CELL
- B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV
- (2021) Johannes F. Scheid et al. CELL
- Combination therapy with tocilizumab and dexamethasone cost-effectively reduces Coronavirus disease 2019 mortality
- (2021) Pranay Sinha et al. CLINICAL INFECTIOUS DISEASES
- Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February
- (2021) Daniel J Grint et al. Eurosurveillance
- Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma
- (2021) Shaukat Ali et al. Immunotherapy
- SARS-CoV-2 spike therapeutic antibodies in the age of variants
- (2021) Alina Baum et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Integrated Biophysical Modeling of the SARS-CoV-2 Spike Protein Binding and Allosteric Interactions with Antibodies
- (2021) Gennady M. Verkhivker et al. JOURNAL OF PHYSICAL CHEMISTRY B
- An update: the emerging evidence of complement involvement in COVID-19
- (2021) Qin Li et al. MEDICAL MICROBIOLOGY AND IMMUNOLOGY
- Antibody-Dependent Enhancement and the Critical Pattern of COVID-19: Possibilities and Considerations
- (2021) Fatemeh Farshadpour et al. MEDICAL PRINCIPLES AND PRACTICE
- Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment
- (2021) Norma A. Valdez-Cruz et al. Microbial Cell Factories
- Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice
- (2021) Raoul De Gasparo et al. NATURE
- Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
- (2021) Sandile Cele et al. NATURE
- Generation of recombinant hyperimmune globulins from diverse B-cell repertoires
- (2021) Sheila M. Keating et al. NATURE BIOTECHNOLOGY
- SARS-CoV-2 infection of the oral cavity and saliva
- (2021) Ni Huang et al. NATURE MEDICINE
- Mol* Viewer: modern web app for 3D visualization and analysis of large biomolecular structures
- (2021) David Sehnal et al. NUCLEIC ACIDS RESEARCH
- Risk factors for COVID-19 mortality: The effect of convalescent plasma administration
- (2021) Martín R. Salazar et al. PLoS One
- Neutralising antibody escape of SARS‐CoV‐2 spike protein: Risk assessment for antibody‐based Covid‐19 therapeutics and vaccines
- (2021) Daniele Focosi et al. REVIEWS IN MEDICAL VIROLOGY
- The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
- (2021) Bryan E. Jones et al. Science Translational Medicine
- COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions
- (2021) Opeyemi S. Adeniji et al. mBio
- Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma
- (2021) Harini Natarajan et al. mBio
- Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection
- (2021) Ge Song et al. Nature Communications
- A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes
- (2021) Yu Guo et al. Nature Communications
- A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies
- (2021) Chunyan Wang et al. Nature Communications
- A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection
- (2021) Ami Miller et al. Scientific Reports
- Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19
- (2021) Guillermo León et al. Scientific Reports
- Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases
- (2021) Tharmala Tharmalingam et al. Human Vaccines & Immunotherapeutics
- No Evidence for Human Monocyte-Derived Macrophage Infection and Antibody-Mediated Enhancement of SARS-CoV-2 Infection
- (2021) Obdulio García-Nicolás et al. Frontiers in Cellular and Infection Microbiology
- Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis
- (2021) Qiu Wei et al. Infectious Diseases of Poverty
- A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain
- (2021) Ling Niu et al. Frontiers in Immunology
- Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11
- (2021) Juliette Fedry et al. Science Advances
- Targeting the Complement Cascade in the Pathophysiology of COVID-19 Disease
- (2021) Nicole Ng et al. Journal of Clinical Medicine
- Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6
- (2021) Robert Flisiak et al. Journal of Clinical Medicine
- Structure and function analysis of a potent human neutralizing antibody CA521FALA against SARS-CoV-2
- (2021) Deyong Song et al. Communications Biology
- Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2
- (2021) Kushal Suryamohan et al. Communications Biology
- Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients
- (2021) Samir Awasthi et al. Cell Death Discovery
- Previous Humoral Immunity to the Endemic Seasonal Alphacoronaviruses NL63 and 229E Is Associated with Worse Clinical Outcome in COVID-19 and Suggests Original Antigenic Sin
- (2021) Daniele Focosi et al. Life-Basel
- In vitro data suggest that Indian delta variant B.1.617 of SARS‐CoV‐2 escapes neutralization by both receptor affinity and immune evasion
- (2021) Gilles Augusto et al. ALLERGY
- An antibody engineering platform using amino acid networks: A case study in development of antiviral therapeutics
- (2021) Debbie Ching Ping Lee et al. ANTIVIRAL RESEARCH
- Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant
- (2021) Dong-Kyun Ryu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
- (2021) Dapeng Li et al. CELL
- Tackling COVID-19 with neutralizing monoclonal antibodies
- (2021) Davide Corti et al. CELL
- An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies
- (2021) Yafei Liu et al. CELL
- The incubation period distribution of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis
- (2021) Hualei Xin et al. CLINICAL INFECTIOUS DISEASES
- Investigation of nonsynonymous mutations in the spike protein of SARS-CoV-2 and its interaction with the ACE2 receptor by molecular docking and MM/GBSA approach
- (2021) Reem Y. Aljindan et al. COMPUTERS IN BIOLOGY AND MEDICINE
- Neutralization of SARS‐CoV‐2 by highly potent, hyperthermostable, and mutation‐tolerant nanobodies
- (2021) Thomas Güttler et al. EMBO JOURNAL
- Do we need bamlanivimab? Is etesevimab a key to treating Covid-19?
- (2021) Sheila A Doggrell EXPERT OPINION ON BIOLOGICAL THERAPY
- Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations
- (2021) Daniele Focosi et al. Expert Review of Vaccines
- Complement dysregulation is associated with severe COVID-19 illness
- (2021) Jia Yu et al. HAEMATOLOGICA
- Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy
- (2021) Irfan Ullah et al. IMMUNITY
- A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope
- (2021) Laura A. VanBlargan et al. IMMUNITY
- Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species
- (2021) Ruoke Wang et al. IMMUNITY
- Structures of synthetic nanobody–SARS-CoV-2–receptor binding domain complexes reveal distinct sites of interaction
- (2021) Javeed Ahmad et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-CoV-2 variants
- (2021) Veronika Tchesnokova et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations
- (2021) Shane Miersch et al. JOURNAL OF MOLECULAR BIOLOGY
- No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients
- (2021) Ruxandra Burlacu et al. MEDICINE
- Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy
- (2021) Rachel Yamin et al. NATURE
- Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York
- (2021) Medini K. Annavajhala et al. NATURE
- In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
- (2021) Rita E. Chen et al. NATURE
- Broad sarbecovirus neutralization by a human monoclonal antibody
- (2021) M. Alejandra Tortorici et al. NATURE
- Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants
- (2021) Zhiqiang Ku et al. NATURE
- SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
- (2021) Tyler N. Starr et al. NATURE
- Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants
- (2021) Jianliang Xu et al. NATURE
- Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
- (2021) Philippe Bégin et al. NATURE MEDICINE
- The biological and clinical significance of emerging SARS-CoV-2 variants
- (2021) Kaiming Tao et al. NATURE REVIEWS GENETICS
- Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
- (2021) Michael Dougan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Convalescent Plasma for High-Risk Outpatients with Covid-19
- (2021) Frederick K. Korley et al. NEW ENGLAND JOURNAL OF MEDICINE
- The impact of tocilizumab on respiratory support states transition and clinical outcomes in COVID-19 patients. A Markov model multi-state study
- (2021) Jovana Milic et al. PLoS One
- The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody
- (2021) Conrad E. Z. Chan et al. PLoS One
- SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma
- (2021) Emanuele Andreano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
- (2021) Lingshu Wang et al. SCIENCE
- Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
- (2021) Meng Yuan et al. SCIENCE
- Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence
- (2021) Moritz U. G. Kraemer et al. SCIENCE
- Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
- (2021) Kathryn M. Hastie et al. SCIENCE
- Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants
- (2021) Yongfei Cai et al. SCIENCE
- Broad betacoronavirus neutralization by a stem helix–specific human antibody
- (2021) Dora Pinto et al. SCIENCE
- Antibody fucosylation predicts disease severity in secondary dengue infection
- (2021) Stylianos Bournazos et al. SCIENCE
- Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies
- (2021) Gabriele Cerutti et al. STRUCTURE
- Are We Forgetting About IgA? A Re‐examination of Coronavirus Disease 2019 Convalescent Plasma
- (2021) Hans Verkerke et al. TRANSFUSION
- Rabies virus neutralizing activity, pharmacokinetics, and safety of the monoclonal antibody mixture SYN023 in combination with rabies vaccination: Results of a phase 2, randomized, blinded, controlled trial
- (2021) J. Bruce McClain et al. VACCINE
- Intravenous immunoglobulin-based adjuvant therapy for severe COVID-19: a single-center retrospective cohort study
- (2021) Xiao Hou et al. Virology Journal
- Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections
- (2021) Shamus P. Keeler et al. Viruses-Basel
- Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome
- (2021) Oleksandr Oliynyk et al. Viruses-Basel
- Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection
- (2021) Sandro Halwe et al. Viruses-Basel
- Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers
- (2021) Edurne Rujas et al. Nature Communications
- Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes
- (2021) Dapeng Sun et al. Nature Communications
- Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies
- (2021) Allison J. Greaney et al. Nature Communications
- Single-cell transcriptome of bronchoalveolar lavage fluid reveals sequential change of macrophages during SARS-CoV-2 infection in ferrets
- (2021) Jeong Seok Lee et al. Nature Communications
- Nanoscale spatial dependence of avidity in an IgG1 antibody
- (2021) Agnieszka Jendroszek et al. Scientific Reports
- A highly potent antibody effective against SARS-CoV-2 variants of concern
- (2021) Craig Fenwick et al. Cell Reports
- Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition
- (2021) Kevin J. Kramer et al. Cell Reports
- A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations
- (2021) Federico Bertoglio et al. Cell Reports
- Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7
- (2021) Bo Meng et al. Cell Reports
- Structural and energetic profiling of SARS-CoV-2 receptor binding domain antibody recognition and the impact of circulating variants
- (2021) Rui Yin et al. PLoS Computational Biology
- Intranasal gene therapy to prevent infection by SARS-CoV-2 variants
- (2021) Joshua J. Sims et al. PLoS Pathogens
- An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope
- (2021) Zezhong Liu et al. Protein & Cell
- Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand the human ACE2 receptor on binding affinity and kinetics
- (2021) Michael I Barton et al. eLife
- Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality
- (2021) Arturo Casadevall et al. eLife
- Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19
- (2021) Xavier Mariette et al. JAMA Internal Medicine
- Immunoglobulin Y for Potential Diagnostic and Therapeutic Applications in Infectious Diseases
- (2021) Lucia Lee et al. Frontiers in Immunology
- HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function
- (2021) Simone I. Richardson et al. Frontiers in Immunology
- Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern
- (2021) Ashlesha Deshpande et al. Frontiers in Immunology
- Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021
- (2021) Catherine M. Brown et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- CD209L/L-SIGN and CD209/DC-SIGN Act as Receptors for SARS-CoV-2
- (2021) Razie Amraei et al. ACS Central Science
- SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution
- (2021) Jiří Zahradník et al. Nature Microbiology
- SARS-CoV-2 Entry: At the Crossroads of CD147 and ACE2
- (2021) Claudio Fenizia et al. Cells
- hACE2 Fc-neutralization antibody cocktail provides synergistic protection against SARS-CoV-2 and its spike RBD variants
- (2021) Junli Liu et al. Cell Discovery
- SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India
- (2021) Sarah Cherian et al. Microorganisms
- Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection
- (2021) Arnaud John Kombe Kombe et al. Frontiers in Molecular Biosciences
- Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern
- (2021) Juanjie Tang et al. iScience
- The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections
- (2021) Mohamed Moubarak et al. Life-Basel
- 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19
- (2021) Alessia Alunno et al. ANNALS OF THE RHEUMATIC DISEASES
- Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein
- (2021) Hristo L. Svilenov et al. ANTIVIRAL RESEARCH
- The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2
- (2021) Dong-Kyun Ryu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- COVID-19 Convalescent plasma
- (2021) Aaron Tobian et al. BLOOD
- The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
- (2021) Markus Hoffmann et al. CELL
- Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner
- (2021) Roanne Keeton et al. Cell Host & Microbe
- Receptome profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2
- (2021) Yunqing Gu et al. CELL RESEARCH
- Regdanvimab: First Approval
- (2021) Yahiya Y. Syed DRUGS
- Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)
- (2021) Harrison C. Bergeron et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review
- (2021) Daniele Focosi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies
- (2021) Saathvik R. Kannan et al. JOURNAL OF AUTOIMMUNITY
- Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins
- (2021) José María Díez et al. JOURNAL OF INFECTIOUS DISEASES
- Relative instantaneous reproduction number of Omicron SARS‐CoV‐2 variant with respect to the Delta variant in Denmark
- (2021) Kimihito Ito et al. JOURNAL OF MEDICAL VIROLOGY
- Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
- (2021) Wesley H. Self et al. LANCET INFECTIOUS DISEASES
- Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries
- (2021) Tom Z. Yuan et al. mAbs
- A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus
- (2021) Allison August et al. NATURE MEDICINE
- Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
- (2021) Anil Gupta et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 spreads through cell-to-cell transmission
- (2021) Cong Zeng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target
- (2021) Tapan Behl et al. SCIENCE OF THE TOTAL ENVIRONMENT
- SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity
- (2021) Sabari Nath Neerukonda et al. Viruses-Basel
- Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants
- (2021) Tingting Li et al. Nature Communications
- Cytokine signature and COVID-19 prediction models in the two waves of pandemics
- (2021) Serena Cabaro et al. Scientific Reports
- Tocilizumab reduces COVID-19 mortality and pathology in a dose and timing-dependent fashion: a multi-centric study
- (2021) Alejandro Durán-Méndez et al. Scientific Reports
- A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration
- (2021) Xilin Wu et al. Cell Reports
- Efficacy of Tocilizumab in COVID-19: Single-Center Experience
- (2021) Safak Kaya et al. Biomed Research International
- Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients
- (2021) Mila B. Ortigoza et al. JAMA Internal Medicine
- SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells
- (2021) Hanjun Zhao et al. Emerging Microbes & Infections
- Relative Reproduction Number of SARS-CoV-2 Omicron (B.1.1.529) Compared with Delta Variant in South Africa
- (2021) Hiroshi Nishiura et al. Journal of Clinical Medicine
- Can the Nasal Cavity Help Tackle COVID-19?
- (2021) Bissera Pilicheva et al. Pharmaceutics
- Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa
- (2021) F. Abdullah et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Immunoinformatics‐aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019‐nCoV
- (2020) Vargab Baruah et al. JOURNAL OF MEDICAL VIROLOGY
- Convalescent plasma as a potential therapy for COVID-19
- (2020) Long Chen et al. LANCET INFECTIOUS DISEASES
- Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2
- (2020) Renhong Yan et al. SCIENCE
- Influenza A Virus Antibodies with Antibody-Dependent Cellular Cytotoxicity Function
- (2020) Rongyuan Gao et al. Viruses-Basel
- In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies
- (2020) Ami Patel et al. BIODRUGS
- SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract
- (2020) Yixuan J. Hou et al. CELL
- Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
- (2020) Evangelos J. Giamarellos-Bourboulis et al. Cell Host & Microbe
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
- (2020) Chenguang Shen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The convalescent sera option for containing COVID-19
- (2020) Arturo Casadevall et al. JOURNAL OF CLINICAL INVESTIGATION
- Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop
- (2020) Javier A. Jaimes et al. JOURNAL OF MOLECULAR BIOLOGY
- A human neutralizing antibody targets the receptor binding site of SARS-CoV-2
- (2020) Rui Shi et al. NATURE
- Human neutralizing antibodies elicited by SARS-CoV-2 infection
- (2020) Bin Ju et al. NATURE
- Viral and host factors related to the clinical outcome of COVID-19
- (2020) Xiaonan Zhang et al. NATURE
- Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
- (2020) Dora Pinto et al. NATURE
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
- (2020) Jun Lan et al. NATURE
- Structural basis of receptor recognition by SARS-CoV-2
- (2020) Jian Shang et al. NATURE
- Virological assessment of hospitalized patients with COVID-2019
- (2020) Roman Wölfel et al. NATURE
- SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes
- (2020) Waradon Sungnak et al. NATURE MEDICINE
- Effectiveness of convalescent plasma therapy in severe COVID-19 patients
- (2020) Kai Duan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A human monoclonal antibody blocking SARS-CoV-2 infection
- (2020) Chunyan Wang et al. Nature Communications
- Neutralization of hepatitis B virus by a novel DNA-encoded monoclonal antibody
- (2020) Urvi S. Zankharia et al. Human Vaccines & Immunotherapeutics
- The hallmarks of COVID-19 disease
- (2020) Daolin Tang et al. PLoS Pathogens
- Immunoglobulin fragment F(ab’)2 against RBD potently neutralizes SARS-CoV-2 in vitro
- (2020) Xiaoyan Pan et al. ANTIVIRAL RESEARCH
- Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
- (2020) Daniel Wrapp et al. CELL
- Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells
- (2020) Yunlong Cao et al. CELL
- Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!
- (2020) Alan A. Nguyen et al. CLINICAL IMMUNOLOGY
- Impact of SARS-CoV-2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients with Coronavirus Disease 2019
- (2020) Reed Magleby et al. CLINICAL INFECTIOUS DISEASES
- Convalescent Plasma Therapy for COVID-19: State of the Art
- (2020) Daniele Focosi et al. CLINICAL MICROBIOLOGY REVIEWS
- An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review
- (2020) Rajeswari Somasundaram et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection
- (2020) Wafaa B. Alsoussi et al. JOURNAL OF IMMUNOLOGY
- Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review
- (2020) Sharana Mahomed et al. JOURNAL OF INFECTIOUS DISEASES
- The protein expression profile of ACE2 in human tissues
- (2020) Feria Hikmet et al. Molecular Systems Biology
- Convergent antibody responses to SARS-CoV-2 in convalescent individuals
- (2020) Davide F. Robbiani et al. NATURE
- Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
- (2020) Lihong Liu et al. NATURE
- Potently neutralizing and protective human antibodies against SARS-CoV-2
- (2020) Seth J. Zost et al. NATURE
- Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
- (2020) Seth J. Zost et al. NATURE MEDICINE
- Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient
- (2020) Daming Zhou et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody
- (2020) Mangaiarkarasi Asokan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
- (2020) Xiangyang Chi et al. SCIENCE
- Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
- (2020) Alina Baum et al. SCIENCE
- Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
- (2020) Thomas F. Rogers et al. SCIENCE
- Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2
- (2020) Kui K. Chan et al. SCIENCE
- Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
- (2020) Johanna Hansen et al. SCIENCE
- Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
- (2020) Zhe Lv et al. SCIENCE
- Distinct conformational states of SARS-CoV-2 spike protein
- (2020) Yongfei Cai et al. SCIENCE
- Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
- (2020) Philip J. M. Brouwer et al. SCIENCE
- Broad neutralization of SARS-related viruses by human monoclonal antibodies
- (2020) Anna Z. Wec et al. SCIENCE
- The true historical origin of convalescent plasma therapy
- (2020) Piero Marson et al. TRANSFUSION AND APHERESIS SCIENCE
- Fruitful neutralizing antibody pipeline brings hope to defeat SARS-Cov-2
- (2020) Alex Renn et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Early experience with convalescent plasma as immunotherapy for COVID‐19 in China: Knowns and unknowns
- (2020) Binzhen Chen et al. VOX SANGUINIS
- Nonclinical safety, tolerance and pharmacodynamics evaluation for meplazumab treating chloroquine-resistant Plasmodium falciparum
- (2020) Kun Zhang et al. Acta Pharmaceutica Sinica B
- Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies
- (2020) Meng Yuan et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?
- (2020) Shubham Atal et al. BIODRUGS
- The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial
- (2020) Naser Gharebaghi et al. BMC INFECTIOUS DISEASES
- A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model
- (2020) Jakob Kreye et al. CELL
- SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2
- (2020) Thomas Mandel Clausen et al. CELL
- Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy
- (2020) Shuo Du et al. CELL
- Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
- (2020) Luca Piccoli et al. CELL
- High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models
- (2020) Wei Li et al. CELL
- Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike
- (2020) Jiandong Huo et al. Cell Host & Microbe
- Complement activation in the disease course of COVID-19 and its effects on clinical outcomes
- (2020) Aline H de Nooijer et al. JOURNAL OF INFECTIOUS DISEASES
- Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection
- (2020) Stylianos Bournazos et al. NATURE
- SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
- (2020) Christopher O. Barnes et al. NATURE
- Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2
- (2020) Colton J. Bracken et al. Nature Chemical Biology
- Engineered ACE2 receptor traps potently neutralize SARS-CoV-2
- (2020) Anum Glasgow et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Neuropilin-1 is a host factor for SARS-CoV-2 infection
- (2020) James L. Daly et al. SCIENCE
- Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity
- (2020) Ludovico Cantuti-Castelvetri et al. SCIENCE
- Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms
- (2020) M. Alejandra Tortorici et al. SCIENCE
- An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction
- (2020) Leo Hanke et al. Nature Communications
- A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction
- (2020) Monir Ejemel et al. Nature Communications
- Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
- (2020) Anup Agarwal et al. BMJ-British Medical Journal
- An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain
- (2020) Nicholas C. Wu et al. Cell Reports
- Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping
- (2020) Yan Lu et al. Journal of Immunology Research
- Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
- (2020) Wen Shi Lee et al. Nature Microbiology
- Deleterious Outcomes in Long-Hauler COVID-19: The Effects of SARS-CoV-2 on the CNS in Chronic COVID Syndrome
- (2020) Abdul Mannan Baig ACS Chemical Neuroscience
- Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection
- (2020) Hangping Yao et al. CELL RESEARCH
- Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection
- (2020) Vanessa Monteil et al. EMBO Molecular Medicine
- Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo
- (2020) Alexandra Schäfer et al. JOURNAL OF EXPERIMENTAL MEDICINE
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
- (2020) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
- (2020) Peter Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity
- (2020) Mads Delbo Larsen et al. SCIENCE
- Enhanced SARS-CoV-2 neutralization by dimeric IgA
- (2020) Zijun Wang et al. Science Translational Medicine
- Neutralizing antibodies targeting SARS-CoV-2 spike protein
- (2020) Shi Xiaojie et al. Stem Cell Research
- High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme
- (2020) Thomas J. Esparza et al. Scientific Reports
- A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters
- (2020) Anna C. Fagre et al. Frontiers in Immunology
- Neutralizing antibodies for the treatment of COVID-19
- (2020) Shibo Jiang et al. Nature Biomedical Engineering
- ALTHEA Gold Libraries™: Antibody libraries for therapeutic antibody discovery
- (2019) Philippe Valadon et al. mAbs
- Zika Virus: Origins, Pathological Action, and Treatment Strategies
- (2019) Kirill Gorshkov et al. Frontiers in Microbiology
- VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design
- (2019) Fang Chen et al. Current Opinion in Virology
- Roles of GM-CSF in the Pathogenesis of Autoimmune Diseases: An Update
- (2019) Noushin Lotfi et al. Frontiers in Immunology
- Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1
- (2019) George K. Lewis et al. Frontiers in Immunology
- New antibody-based prevention and treatment options for influenza
- (2019) Koen Sedeyn et al. ANTIVIRAL RESEARCH
- Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry
- (2019) Yushun Wan et al. JOURNAL OF VIROLOGY
- Influenza Hemagglutinin Structures and Antibody Recognition
- (2019) Nicholas C. Wu et al. Cold Spring Harbor Perspectives in Medicine
- Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study)
- (2018) Tobias Welte et al. INTENSIVE CARE MEDICINE
- C5a receptor1 inhibition alleviates influenza virus-induced acute lung injury
- (2018) Nianping Song et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- The “less-is-more” in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity
- (2018) Natasha A. Pereira et al. mAbs
- HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions
- (2018) Cody S. Nelson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Viral envelope-specific antibodies in chronic hepatitis B virus infection
- (2018) Davide Corti et al. Current Opinion in Virology
- Back to the Future: Lessons Learned From the 1918 Influenza Pandemic
- (2018) Kirsty R. Short et al. Frontiers in Cellular and Infection Microbiology
- Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir
- (2017) Shariq Mujib et al. JOURNAL OF VIROLOGY
- Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
- (2017) Jesper Pallesen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Current progress in innovative engineered antibodies
- (2017) William R. Strohl Protein & Cell
- Antibody therapies for the prevention and treatment of viral infections
- (2017) Georgina Salazar et al. npj Vaccines
- A novel antibody discovery platform identifies anti-influenza A broadly neutralizing antibodies from human memory B cells
- (2016) Xiaodong Xiao et al. mAbs
- Efficacy of Convalescent Plasma in Relation to Dose of Ebola Virus Antibodies
- (2016) Johan van Griensven et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cross-Reactivity, Epitope Spreading, andDe NovoImmune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines
- (2015) Mayumi Nakagawa et al. Clinical and Vaccine Immunology
- Administration of Brincidofovir and Convalescent Plasma in a Patient With Ebola Virus Disease
- (2015) Diana F. Florescu et al. CLINICAL INFECTIOUS DISEASES
- Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases
- (2015) Kuan Rong Chan et al. Expert Review of Anti-Infective Therapy
- Fc receptors in antibody-dependent enhancement of viral infections
- (2015) Adam Taylor et al. IMMUNOLOGICAL REVIEWS
- Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail
- (2015) Jeffrey R. Kugelman et al. Cell Reports
- Species-Specific Chromosome Engineering Greatly Improves Fully Human Polyclonal Antibody Production Profile in Cattle
- (2015) Hiroaki Matsushita et al. PLoS One
- Human Antibody Production in Transgenic Animals
- (2014) Marianne Brüggemann et al. ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
- Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins
- (2014) Sheng-Fan Wang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system
- (2014) L. Guilleminault et al. JOURNAL OF CONTROLLED RELEASE
- Triple Immunoglobulin Gene Knockout Transchromosomic Cattle: Bovine Lambda Cluster Deletion and Its Effect on Fully Human Polyclonal Antibody Production
- (2014) Hiroaki Matsushita et al. PLoS One
- Molecular Signatures of Hemagglutinin Stem-Directed Heterosubtypic Human Neutralizing Antibodies against Influenza A Viruses
- (2014) Yuval Avnir et al. PLoS Pathogens
- Nanobodies: Natural Single-Domain Antibodies
- (2013) Serge Muyldermans Annual Review of Biochemistry
- Monoclonal antibodies for prophylactic and therapeutic use against viral infections
- (2013) Leonard Both et al. VACCINE
- Shaping of Human Germline IgH Repertoires Revealed by Deep Sequencing
- (2012) K. Larimore et al. JOURNAL OF IMMUNOLOGY
- Human Peripheral Blood Antibodies with Long HCDR3s Are Established Primarily at Original Recombination Using a Limited Subset of Germline Genes
- (2012) Bryan S. Briney et al. PLoS One
- Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection
- (2011) I. F. Hung et al. CLINICAL INFECTIOUS DISEASES
- Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology
- (2011) Jody D. Berry et al. New Biotechnology
- How Innate Immune Mechanisms Contribute to Antibody-Enhanced Viral Infections
- (2010) S. Ubol et al. Clinical and Vaccine Immunology
- Secretory IgA: Arresting Microbial Pathogens at Epithelial Borders
- (2010) Nicholas J. Mantis et al. IMMUNOLOGICAL INVESTIGATIONS
- Enhanced antibody half-life improves in vivo activity
- (2010) Jonathan Zalevsky et al. NATURE BIOTECHNOLOGY
- A Nanoengineering Approach for Investigation and Regulation of Protein Immobilization
- (2008) Yih Horng Tan et al. ACS Nano
- Structural characterization of a human Fc fragment engineered for lack of effector functions
- (2008) Vaheh Oganesyan et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More